News and Trends 3 Jan 2023 Sensorion announces first patient enrolled in cisplatin-induced ototoxicity trial Sensorion has announced that the first patient has been enrolled in its phase 2a proof of concept clinical trial of SENS-401 (Arazasetron) in patients suffering from cisplatin-induced ototoxicity. Cisplatin and other platinum-based compounds are essential chemotherapeutic agents for many cancers. A serious side effect of these therapies is ototoxicity, or permanent and irreversible hearing loss, […] January 3, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 3 Jan 2023 Blacksmith Medicines merging with Forge Therapeutics Blacksmith Medicines, Inc., and Forge Therapeutics have signed a definitive merger agreement. This will create a biopharma company dedicated to discovering and developing medicines targeting a large class of proteins called metalloenzymes. The initial focus will be on oncology and infection. “We are excited to unveil the merger of Blacksmith and Forge, which we believe […] January 3, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 1 Jan 2023 Watch: Addressing IP with Starting Bloch Starting Bloch is a French-headquartered company helping companies navigate the world of IP and patents. The company’s Patman platform was developed to assist companies with patents, licenses and trademarks. The company also assists companies addressing fundraising, as well as helping with management and tech transfer. Patman gives companies a calendar of events to address issues […] January 1, 2023 - 1 minutemin - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 1 Jan 2023 Watch: Roquefort Therapeutics at BioFIT Roquefort Therapeutics is a biotech company developing first-in-class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma. Since listing in March 2021, Roquefort Therapeutics has successfully acquired Lyramid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth […] January 1, 2023 - 1 minutemin - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 29 Dec 2022 Watch: Zoetis looks for partnerships at BioFIT Animal health company, Zoetis, has a pipeline of medicines, vaccines, diagnostics and technologies for livestock and pets. Active in more than 100 countries, Zoetis generated revenue of $7.8 billion in 2021, and has approximately 12,100 employees. The company recently announced a collaboration with the partners of the Pastoral Greenhouse Gas Research Consortium, and the New […] December 29, 2022 - 1 minutemin - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 23 Dec 2022 Watch: Eva Hoffmann talks about genetics and fertility Eva R. Hoffmann is the Professor in Molecular Genetics at the Department of Cellular and Molecular Medicine at the University of Copenhagen in Denmark. She is involved in the Molecular Aging Program, Medical Genetics Program and the Centre for Chromosome Stability. Hoffmann’s laboratory investigates the role of the DNA damage response and cell cycle proteins in […] December 23, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 23 Dec 2022 Watch: Something to SmiLe about in southern Sweden SmiLe Incubator is a life science business incubator based in Medicon Village in Lund, Sweden. SmiLe helps entrepreneurs commercialize their ideas. There are currently 30 companies in the SmiLe Incubator that, together with alumni companies, have attracted more than €664 million ($705 million) in venture capital since 2014. SmiLe offers business coaching, a broad international […] December 23, 2022 - 1 minutemin - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 23 Dec 2022 Watch: The Medicon Valley Alliance celebrates 25th anniversary The Medicon Valley Alliance (MVA) is a non-profit membership organization in the Danish-Swedish life science cluster Medicon Valley. It covers eastern Denmark, which includes the capital, Copenhagen, as well as the southern Sweden region of Skåne, which includes Malmö and Lund. The organization includes more than 300 members, and encompasses universities, hospitals, human life science […] December 23, 2022 - 1 minutemin - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 23 Dec 2022 Affibody signs €20 million loan agreement Affibody Medical AB has received a €20 million ($21.2 million) venture debt loan facility from the European Investment Bank, EIB, backed by the InvestEU program. The investment will support Affibody’s research and development activities in Europe of the next-generation biopharmaceuticals targeting unmet medical needs in the immunology and oncology fields. “We are very pleased and […] December 23, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 23 Dec 2022Beyond Biotech podcast 27: Cradle, Rani Therapeutics This week, in our last podcast of 2022, we have two guests. We have conversations with Talat Imran, CEO of Rani Therapeutics; and Stef van Grieken, CEO and co-founder of Cradle. Rani Therapeutics – aiming to remove the pain of needles Rani Therapeutics Holdings, Inc., a clinical-stage biotherapeutics company focused on the oral delivery of […] December 23, 2022 Share WhatsApp Twitter Linkedin Email
News and Trends 23 Dec 2022 Mersana Therapeutics and Merck to develop novel ADCs Mersana Therapeutics, Inc. has announced a research collaboration and commercial license agreement with a subsidiary of Merck KGaA, Darmstadt, Germany to discover novel Immunosynthen antibody drug conjugates (ADCs) directed against up to two targets. Immunosynthen, Mersana Therapeutics’ proprietary STING-agonist ADC platform, is designed to generate systemically administered ADCs that locally activate STING signaling in both […] December 23, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 23 Dec 2022 Merck and Kelun-Biotech collaborating on seven ADC cancer candidates Merck (MSD outside of the U.S. and Canada), and Kelun-Biotech (a holding subsidiary of Sichuan Kelun Pharmaceutical Co., Ltd), have entered into an exclusive license and collaboration agreement to develop seven investigational preclinical antibody-drug conjugates (ADC) for the treatment of cancer. “Advances in ADC technologies are yielding a new generation of candidates designed to more […] December 23, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email